Why the study?
Timely neuroimaging is limited during ECMO support, making bedside blood-based biomarkers for acute brain injury clinically important.
Do plasma biomarkers accurately detect acute brain injury in patients on ECMO support?
Do plasma biomarkers accurately detect acute brain injury in patients on ECMO support?
Blood-based biomarkers may offer a bedside tool for early detection of acute brain injury in patients on ECMO support, overcoming limitations of timely neuroimaging.
Supports investigation of plasma biomarkers for bedside brain injury detection on ECMO; leaves open prospective validation before clinical adoption.
Extracorporeal membrane oxygenation (ECMO) is a life-saving intervention for patients with refractory cardiorespiratory failure. Despite its benefits, ECMO carries a significant risk of neurological complications, including acute brain injury (ABI). Although standardized neuromonitoring and neurological care have been shown to improve early detection of ABI, the inability to perform neuroimaging in a timely manner is a major limitation in the accurate diagnosis of neurological complications. Therefore, blood-based biomarkers capable of detecting ongoing brain injury at the bedside are of great clinical significance. This review aims to provide a concise review of the current literature on plasma biomarkers for ABI in patients on ECMO support.
No takes yet. Share an insight, caveat, or question.
Kapoor et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: